Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhiguo Luo

Showing results (121-130 of 126) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 126 results.
European Journal of Cancer (Oxford, England : 1990)|March 13, 2024
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanomaXiaoting Wei, Zhengyun Zou, Weizhen Zhang, et al.
The Lancet. Oncology|July 28, 2024
Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trialXin Liu, Xiaowei Zhang, Shiyu Jiang, et al.
The Lancet. Oncology|February 16, 2026
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 studyReinhard Dummer, Jun Guo, Jason J Luke, et al.
Biomarker Research|January 9, 2026
Machine learning-driven proteomics classifier deciphers tumor origins of primary and metastatic squamous cell carcinomasTianqi Gong, I Weng Lao, Chan Fong Chio, et al.
Cancer Biology & Medicine|December 10, 2020
Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer AssociationYi Ba, Yuankai Shi, Wenqi Jiang, et al.
Cancer Communications (London, England)|June 29, 2021
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trialYuankai Shi, Kaijian Lei, Yuming Jia, et al.
Pageof 13

Showing results (121-130 of 126) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 126 results.
European Journal of Cancer (Oxford, England : 1990)|March 13, 2024
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanomaXiaoting Wei, Zhengyun Zou, Weizhen Zhang, et al.
The Lancet. Oncology|July 28, 2024
Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trialXin Liu, Xiaowei Zhang, Shiyu Jiang, et al.
The Lancet. Oncology|February 16, 2026
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 studyReinhard Dummer, Jun Guo, Jason J Luke, et al.
Biomarker Research|January 9, 2026
Machine learning-driven proteomics classifier deciphers tumor origins of primary and metastatic squamous cell carcinomasTianqi Gong, I Weng Lao, Chan Fong Chio, et al.
Cancer Biology & Medicine|December 10, 2020
Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer AssociationYi Ba, Yuankai Shi, Wenqi Jiang, et al.
Cancer Communications (London, England)|June 29, 2021
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trialYuankai Shi, Kaijian Lei, Yuming Jia, et al.
Pageof 13